biostudies-literatureZaorsky NGNCI NIH HHS386-393https://www.ebi.ac.uk/biostudies/studies/S-EPMC7548033biostudies-literatureUnknown126(3)<h4>Background and purpose</h4>To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin.<h4>Materials and methods</h4>Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as "good," "fair," or "poor." The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED₃) and cosmetic outcomes.<h4>Results</h4>A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 yeRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologySkin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.PMC7548033P30 CA006927Zhang EZaorsky NGLee CTGalloway TJfalseSkin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.<h4>Background and purpose</h4>To compare cosmesis and local recurrence (LR) of definitive external beam radiation therapy (EBRT) vs brachytherapy (BT) for indolent basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin.<h4>Materials and methods</h4>Studies including patients with T1-2 N0 SCCs/BCCs treated with definitive EBRT/BT and ≥10 months follow-up were analyzed. The primary endpoint was post-treatment cosmesis, categorized as "good," "fair," or "poor." The secondary endpoint was LR. Mixed effects regression models were used to estimate weighted linear relationships between biologically equivalent doses with α/β = 3 (BED₃) and cosmetic outcomes.<h4>Results</h4>A total of 9965 patients received EBRT and 553 received BT across 24 studies. Mean age was 73 ye2018-01-01T00:00:00Z2018 Mar2025-04-26T11:53:42.671Z2025-04-06T13:51:20.548ZS-EPMC75480332937098510.1016/j.radonc.2017.12.029